0A

Alcon AGLSE Alcon Stock Report

Last reporting period 30 Jun, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

48.37

Mega

Exchange

XLON - London Stock Exchange

0A0D.L Stock Analysis

0A

Neutral

Based on Eyestock quantitative analysis, 0A0D.L`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

56/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

135.0 %

Greatly undervalued

Market cap $B

48.37

Dividend yield

0.65 %

Shares outstanding

491.8 B

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 25,178 full-time employees. The company went IPO on 2019-04-09. The firm research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The firm operates in 60 countries and serves consumers and patients in over 140 countries.

View Section: Eyestock Rating